Details of the Drug

General Information of Drug (ID: DM1IB4Q)

Drug Name
Zolmitriptan
Synonyms
AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1], [2]
Therapeutic Class
Antimigraine Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 287.36
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 84.4-173.8 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 16-25.2 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 40% [3]
Clearance
The clearance of drug is 31.5 mL/min/kg [5]
Elimination
Zolmitriptan is primarily excreted in urine (approximately 65%) and feces (approximately 30%) [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [5]
Metabolism
The drug is metabolized via the liver [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4971 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.75% [7]
Vd
The volume of distribution (Vd) of drug is 7-8.4 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 20 mg/mL [4]
Chemical Identifiers
Formula
C16H21N3O2
IUPAC Name
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
Canonical SMILES
CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
InChI
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
InChIKey
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
Cross-matching ID
PubChem CID
60857
ChEBI ID
CHEBI:10124
CAS Number
139264-17-8
DrugBank ID
DB00315
TTD ID
D0NG7O
VARIDT ID
DR01278
INTEDE ID
DR1733
ACDINA ID
D00743

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [8]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [11]
Monoamine oxidase type A (MAO-A)
Main DME 		DERE4TU AOFA_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Zolmitriptan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Decreased metabolism of Zolmitriptan caused by Methylene blue mediated inhibition of non-CYP450 enzyme. Acquired methaemoglobinaemia [3A93] [57]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Zolmitriptan and Oliceridine. Acute pain [MG31] [58]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Zolmitriptan and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [59]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Zolmitriptan and Desipramine. Attention deficit hyperactivity disorder [6A05] [60]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Zolmitriptan caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [59]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Zolmitriptan and Droxidopa. Autonomic nervous system disorder [8D87] [61]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Zolmitriptan caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [59]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Zolmitriptan and Linezolid. Bacterial infection [1A00-1C4Z] [62]
Norfloxacin DMIZ6W2 Moderate Decreased metabolism of Zolmitriptan caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [59]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Zolmitriptan and Dihydrocodeine. Chronic pain [MG30] [58]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Zolmitriptan and Levomilnacipran. Chronic pain [MG30] [60]
Methadone DMTW6IU Moderate Additive serotonergic effects by the combination of Zolmitriptan and Methadone. Cough [MD12] [58]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Zolmitriptan caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [59]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Zolmitriptan and Ethanol. Cystitis [GC00] [63]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Zolmitriptan and Sertraline. Depression [6A70-6A7Z] [60]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Zolmitriptan and Fluoxetine. Depression [6A70-6A7Z] [60]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Zolmitriptan and Vilazodone. Depression [6A70-6A7Z] [60]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Zolmitriptan and Nefazodone. Depression [6A70-6A7Z] [60]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Zolmitriptan and Paroxetine. Depression [6A70-6A7Z] [60]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Zolmitriptan and Vortioxetine. Depression [6A70-6A7Z] [60]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Zolmitriptan and Duloxetine. Depression [6A70-6A7Z] [60]
Isocarboxazid DMAF1NB Major Decreased metabolism of Zolmitriptan caused by Isocarboxazid mediated inhibition of non-CYP450 enzyme. Depression [6A70-6A7Z] [57]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Zolmitriptan and Milnacipran. Depression [6A70-6A7Z] [60]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Zolmitriptan and Escitalopram. Depression [6A70-6A7Z] [60]
Tranylcypromine DMGB5RE Major Decreased metabolism of Zolmitriptan caused by Tranylcypromine mediated inhibition of non-CYP450 enzyme. Depression [6A70-6A7Z] [57]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Zolmitriptan and Desvenlafaxine. Depression [6A70-6A7Z] [60]
Phenelzine DMHIDUE Major Decreased metabolism of Zolmitriptan caused by Phenelzine mediated inhibition of non-CYP450 enzyme. Depression [6A70-6A7Z] [57]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Zolmitriptan and Trazodone. Depression [6A70-6A7Z] [60]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Zolmitriptan and Mirtazapine. Depression [6A70-6A7Z] [60]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Zolmitriptan and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [64]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Zolmitriptan and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [60]
Cimetidine DMH61ZB Moderate Decreased metabolism of Zolmitriptan caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [65]
Procarbazine DMIK367 Major Decreased metabolism of Zolmitriptan caused by Procarbazine mediated inhibition of non-CYP450 enzyme. Hodgkin lymphoma [2B30] [57]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Zolmitriptan caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [66]
Givosiran DM5PFIJ Moderate Decreased metabolism of Zolmitriptan caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [59]
Capmatinib DMYCXKL Moderate Decreased metabolism of Zolmitriptan caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [59]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Zolmitriptan caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [59]
Exjade DMHPRWG Moderate Decreased metabolism of Zolmitriptan caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [59]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Zolmitriptan and Ozanimod. Multiple sclerosis [8A40] [67]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Zolmitriptan and Palonosetron. Nausea/vomiting [MD90] [68]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Zolmitriptan and Granisetron. Nausea/vomiting [MD90] [68]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Zolmitriptan and Dolasetron. Nausea/vomiting [MD90] [68]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Zolmitriptan and Ondansetron. Nausea/vomiting [MD90] [68]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Zolmitriptan and Sibutramine. Obesity [5B80-5B81] [57]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Zolmitriptan and Lorcaserin. Obesity [5B80-5B81] [69]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Zolmitriptan and Dexfenfluramine. Obesity [5B80-5B81] [60]
Levomethadyl Acetate DM06HG5 Moderate Additive serotonergic effects by the combination of Zolmitriptan and Levomethadyl Acetate. Opioid use disorder [6C43] [58]
Olaparib DM8QB1D Moderate Increased metabolism of Zolmitriptan caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [66]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Zolmitriptan caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [59]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Zolmitriptan and Butorphanol. Pain [MG30-MG3Z] [58]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Zolmitriptan and Oxymorphone. Pain [MG30-MG3Z] [58]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Zolmitriptan and Levorphanol. Pain [MG30-MG3Z] [58]
Hydromorphone DMHP21E Moderate Additive serotonergic effects by the combination of Zolmitriptan and Hydromorphone. Pain [MG30-MG3Z] [58]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Zolmitriptan and Dezocine. Pain [MG30-MG3Z] [58]
Codeine DMJX6ZG Moderate Additive CNS depression effects by the combination of Zolmitriptan and Codeine. Pain [MG30-MG3Z] [58]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Zolmitriptan and Nalbuphine. Pain [MG30-MG3Z] [58]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Zolmitriptan and Buprenorphine. Pain [MG30-MG3Z] [58]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Zolmitriptan and Hydrocodone. Pain [MG30-MG3Z] [58]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Zolmitriptan and Oxycodone. Pain [MG30-MG3Z] [58]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Zolmitriptan caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [59]
Abametapir DM2RX0I Moderate Decreased metabolism of Zolmitriptan caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [70]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Zolmitriptan and Fentanyl. Sensation disturbance [MB40] [60]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Zolmitriptan and Tizanidine. Tonus and reflex abnormality [MB47] [71]
Mexiletine DMCTE9R Moderate Decreased metabolism of Zolmitriptan caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [59]
Propafenone DMPIBJK Moderate Decreased metabolism of Zolmitriptan caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [59]
⏷ Show the Full List of 65 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acesulfame E00341 36573 Flavoring agent
Aspartame E00402 134601 Flavoring agent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zolmitriptan 2.5 mg tablet 2.5 mg Disintegrating Oral Tablet Oral
Zolmitriptan 5 mg tablet 5 mg Disintegrating Oral Tablet Oral
Zolmitriptan 2.5 mg tablet 2.5 mg Oral Tablet Oral
Zolmitriptan 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 60).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020768.
3 Tepper SJ, Chen S, Reidenbach F, Rapoport AM: Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep;53 Suppl 2:62-71. doi: 10.1111/head.12181.
4 BDDCS applied to over 900 drugs
5 FDA Approved Drug Products: ZOMIG/ZOMIG-ZMT (zolmitriptan) oral tablets and nasal spray
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
10 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
11 In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
12 Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
13 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
14 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
15 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
16 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
17 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
18 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
21 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
22 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
23 Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
24 Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
25 Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
26 Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
27 Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
28 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
30 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
31 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
36 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
37 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
38 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
39 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
40 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
41 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
42 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
43 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
44 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
45 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
46 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
47 Company report (NeurAxon)
48 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
49 Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
50 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
51 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
52 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
53 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
54 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
55 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
56 Company report (Fabrekramer)
57 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
58 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
59 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
60 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
61 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
62 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
63 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
64 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
65 Product Information. Zomig (zolmitriptan). Zeneca Pharmaceuticals, Wilmington, DE.
66 Cerner Multum, Inc. "Australian Product Information.".
67 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
68 Canadian Pharmacists Association.
69 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
70 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
71 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.